Andrea Wang‐Gillam

Washington University in St. Louis

Full Professor(heuristic)

Pancreatic and Hepatic Oncology Research · Oncology

h-index49

i10-index128

Publications431

Citations15,645

Grants

16 total · 0 active

NIH #3UM1CA186704-05S1

Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

Amount: $715K
Period: 2014-04-04 → 2023-11-30
PIs: 3
Est. capacity / PI: ~0 students

Awarded at DUKE UNIVERSITY

NIH #5UM1CA186704-05

Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer

Amount: $1.7M
Period: 2014-04-04 → 2023-11-30
PIs: 3
Est. capacity / PI: ~0 students

Awarded at DUKE UNIVERSITY

NIH #5P50CA196510-05

Project 3: Combination inhibition of ERK for pancreatic cancer treatment

Amount: $213K
Period: — → 2022-06-30
PIs: 1
Est. capacity / PI: ~3 students

Awarded at WASHINGTON UNIVERSITY

Student capacity is a rough estimate from remaining award size, split equally among PIs. Actual funding decisions vary.

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 17 of 17

Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12C mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trials
The Lancet. Gastroenterology & hepatology · 2025-12-01
Glecirasib plus sitneprotafib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial
The Lancet Respiratory Medicine · 2025-11-29 · 5 citations
Table S2 from Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study
2025-11-25
Supplementary Data 1 from Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration
2025-11-25
Supplementary Data 2 from Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration
2025-11-25
Table S1 from Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study
2025-11-25
Efficacy and safety of glecirasib in solid tumors with <i>KRAS</i> G12C mutation: A pooled analysis of two phase I/II trials
Cancer Communications · 2025-10-02 · 9 citations
Supplementary Figure 1 from Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer
2025-09-02
Data from Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer
2025-09-02
Supplementary Table 1 from Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer
2025-09-02
Supplementary Table 2 from Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer
2025-09-02
Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer
Clinical Cancer Research · 2025-03-21 · 12 citations
Population Pharmacokinetics of Fruquintinib, a Selective Oral Inhibitor of VEGFR ‐1, ‐2, and ‐3, in Patients with Refractory Metastatic Colorectal Cancer
The Journal of Clinical Pharmacology · 2025-02-19 · 7 citations
Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial
Nature Medicine · 2025-01-06 · 28 citations
Neoantigen DNA vaccines are safe, feasible, and induce neoantigen-specific immune responses in triple-negative breast cancer patients
Genome Medicine · 2024-11-14 · 74 citations
Preliminary Results of Patients with Myelofibrosis (MF) from a Phase I Trial of Jab-8263, a Potent BET Inhibitor
Blood · 2024-11-05 · 1 citations
Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers
UNC Libraries · 2024-09-04

Open author page on OpenAlex →

Andrea Wang‐Gillam

Grants

Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer

Project 3: Combination inhibition of ERK for pancreatic cancer treatment

All Grants

Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer

Project 3: Combination inhibition of ERK for pancreatic cancer treatment

Project 3: Combination inhibition of ERK for pancreatic cancer treatment

Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer

Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer

Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer

Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer

Research Project 2: Development of Synergetic EKR Combinations in PDAC

Research Project 2: Development of Synergetic EKR Combinations in PDAC

Project 3: Combination inhibition of ERK for pancreatic cancer treatment

Research Project 2: Development of Synergetic EKR Combinations in PDAC

Research Project 2: Development of Synergetic EKR Combinations in PDAC

Research Project 2: Development of Synergetic EKR Combinations in PDAC

Project 3: Combination inhibition of ERK for pancreatic cancer treatment

Project 3: Combination inhibition of ERK for pancreatic cancer treatment

Career Trajectory

Research Cluster Map

Potential Collaborators

Recent Publications